Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Medulloblastoma: optimizing care with a multidisciplinary approach.

Thomas A, Noël G.

J Multidiscip Healthc. 2019 Apr 30;12:335-347. doi: 10.2147/JMDH.S167808. eCollection 2019. Review.

2.

Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.

Zhang ZY, Xu J, Ren Y, Li KK, Ng HK, Mao Y, Zhong P, Yao Y, Zhou LF.

PLoS One. 2014 Jun 16;9(6):e99490. doi: 10.1371/journal.pone.0099490. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105742. PLoS One. 2014;9(9):e107855.

3.

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA.

Lancet Oncol. 2018 Jun;19(6):768-784. doi: 10.1016/S1470-2045(18)30204-3. Epub 2018 May 16.

4.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD.

Lancet Oncol. 2016 Apr;17(4):484-495. doi: 10.1016/S1470-2045(15)00581-1. Epub 2016 Mar 12.

5.

Molecular Classification of Medulloblastoma.

Kijima N, Kanemura Y.

Neurol Med Chir (Tokyo). 2016 Nov 15;56(11):687-697. Epub 2016 May 26. Review.

6.

Medulloblastoma molecular dissection: the way toward targeted therapy.

Remke M, Ramaswamy V, Taylor MD.

Curr Opin Oncol. 2013 Nov;25(6):674-81. doi: 10.1097/CCO.0000000000000008. Review.

PMID:
24076581
7.

Current therapy for medulloblastoma.

Gottardo NG, Gajjar A.

Curr Treat Options Neurol. 2006 Jul;8(4):319-34.

PMID:
16942675
8.

Signaling pathway and molecular subgroups of medulloblastoma. Int J Clin Exp Pathol. 2013; 6(7): 1211-22.

Li KK, Lau KM, Ng HK.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):11945. eCollection 2015.

9.

Signaling pathway and molecular subgroups of medulloblastoma.

Li KK, Lau KM, Ng HK.

Int J Clin Exp Pathol. 2013 Jun 15;6(7):1211-22. Print 2013. Review. Erratum in: Int J Clin Exp Pathol. 2015;8(9):11945.

10.

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.

Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC.

Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22.

11.

Radiotherapy Advances in Paediatric Medulloblastoma Treatment.

Padovani L, Horan G, Ajithkumar T.

Clin Oncol (R Coll Radiol). 2019 Mar;31(3):171-181. doi: 10.1016/j.clon.2019.01.001. Epub 2019 Jan 14.

PMID:
30655168
12.

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C.

Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9.

13.

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL.

Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. Review.

14.

Intellectual Outcome in Molecular Subgroups of Medulloblastoma.

Moxon-Emre I, Taylor MD, Bouffet E, Hardy K, Campen CJ, Malkin D, Hawkins C, Laperriere N, Ramaswamy V, Bartels U, Scantlebury N, Janzen L, Law N, Walsh KS, Mabbott DJ.

J Clin Oncol. 2016 Dec;34(34):4161-4170. Epub 2016 Oct 31.

PMID:
27507873
15.

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.

Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schüller U, Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, Pomeroy SL, Dunn S, Triscott J, Jabado N, Fontebasso A, Jones DT, Kool M, Karajannis MA, Gardner SL, Zagzag D, Nunes S, Pimentel J, Mora J, Lipp E, Walter AW, Ryzhova M, Zheludkova O, Kumirova E, Alshami J, Croul SE, Rutka JT, Hawkins C, Tabori U, Codispoti KE, Packer RJ, Pfister SM, Korshunov A, Taylor MD.

Lancet Oncol. 2013 Nov;14(12):1200-7. doi: 10.1016/S1470-2045(13)70449-2. Epub 2013 Oct 17. Erratum in: Lancet Oncol. 2014 Apr;15(4):e154.

16.

Management of high-risk medulloblastoma.

Bouffet E.

Neurochirurgie. 2019 Jun 20. pii: S0028-3770(19)30178-X. doi: 10.1016/j.neuchi.2019.05.007. [Epub ahead of print] Review.

PMID:
31229532
17.

[Craniospinal radiotherapy in combined therapy of medulloblastoma in children and adolescents].

Golubicić I, Bokun J, Nikitović M, Mladenović J, Sarić M, Bekić Z.

Srp Arh Celok Lek. 2003 May-Jun;131(5-6):226-31. Serbian.

18.

Genetic and molecular alterations across medulloblastoma subgroups.

Skowron P, Ramaswamy V, Taylor MD.

J Mol Med (Berl). 2015 Oct;93(10):1075-84. doi: 10.1007/s00109-015-1333-8. Epub 2015 Sep 9. Review.

19.

Case-based review: pediatric medulloblastoma.

Kline CN, Packer RJ, Hwang EI, Raleigh DR, Braunstein S, Raffel C, Bandopadhayay P, Solomon DA, Aboian M, Cha S, Mueller S.

Neurooncol Pract. 2017 Sep;4(3):138-150. doi: 10.1093/nop/npx011. Epub 2017 Aug 11. Review.

20.

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.

von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S.

J Clin Oncol. 2016 Dec;34(34):4151-4160. Epub 2016 Oct 31.

PMID:
27863192

Supplemental Content

Support Center